Alan C Geller1, Richard W Clapp, Arthur J Sober, Lou Gonsalves, Lloyd Mueller, Cindy L Christiansen, Waqas Shaikh, Donald R Miller. 1. Alan C. Geller, Harvard School of Public Health; Richard W. Clapp, Cindy L. Christiansen, and Donald R. Miller, Boston University School of Public Health; Arthur J. Sober, Massachusetts General Hospital; Donald R. Miller, Boston University School of Medicine, Boston; Cindy L. Christiansen and Donald R. Miller, Veterans Administration Center for Health Quality, Outcomes, and Economic Research, Bedford, MA; Lou Gonsalves and Lloyd Mueller, Connecticut Tumor Registry, Hartford, CT; and Waqas Shaikh, SUNY Downstate Medical Center, New York, NY.
Abstract
PURPOSE: Melanoma is the most commonly fatal form of skin cancer, with nearly 50,000 annual deaths worldwide. We sought to assess long-term trends in the incidence and mortality of melanoma in a state with complete and consistent registration. METHODS: We used data from the Connecticut Tumor Registry, the original National Cancer Institute SEER site, to determine trends in invasive melanoma (1950-2007), in situ melanoma (1973-2007), tumor thickness (1993-2007), mortality (1950-2007), and mortality to incidence (1950-2007) among the 19,973 and 3,635 Connecticut residents diagnosed with invasive melanoma (1950-2007) and who died as a result of melanoma (1950-2007), respectively. Main outcome measures included trends in incidence and mortality by age, sex, and birth cohort. RESULTS: In the initial period (1950-1954), a diagnosis of invasive melanoma was rare, with 1.9 patient cases per 100,000 for men and 2.6 patient cases per 100,000 for women. Between 1950 and 2007, overall incidence rates rose more than 17-fold in men (1.9 to 33.5 per 100,000) and more than nine-fold in women (2.6 to 25.3 per 100,000). During these six decades, mortality rates more than tripled in men (1.6 to 4.9 per 100,000) and doubled in women (1.3 to 2.6 per 100,000). Mortality rates were generally stable or decreasing in men and women through age 54 years. CONCLUSION: Unremitting increases in incidence and mortality of melanoma call for a nationally coordinated effort to encourage and promote innovative prevention and early-detection efforts.
PURPOSE:Melanoma is the most commonly fatal form of skin cancer, with nearly 50,000 annual deaths worldwide. We sought to assess long-term trends in the incidence and mortality of melanoma in a state with complete and consistent registration. METHODS: We used data from the Connecticut Tumor Registry, the original National Cancer Institute SEER site, to determine trends in invasive melanoma (1950-2007), in situ melanoma (1973-2007), tumor thickness (1993-2007), mortality (1950-2007), and mortality to incidence (1950-2007) among the 19,973 and 3,635 Connecticut residents diagnosed with invasive melanoma (1950-2007) and who died as a result of melanoma (1950-2007), respectively. Main outcome measures included trends in incidence and mortality by age, sex, and birth cohort. RESULTS: In the initial period (1950-1954), a diagnosis of invasive melanoma was rare, with 1.9 patient cases per 100,000 for men and 2.6 patient cases per 100,000 for women. Between 1950 and 2007, overall incidence rates rose more than 17-fold in men (1.9 to 33.5 per 100,000) and more than nine-fold in women (2.6 to 25.3 per 100,000). During these six decades, mortality rates more than tripled in men (1.6 to 4.9 per 100,000) and doubled in women (1.3 to 2.6 per 100,000). Mortality rates were generally stable or decreasing in men and women through age 54 years. CONCLUSION: Unremitting increases in incidence and mortality of melanoma call for a nationally coordinated effort to encourage and promote innovative prevention and early-detection efforts.
Authors: Ahmedin Jemal; Mona Saraiya; Pragna Patel; Sai S Cherala; Jill Barnholtz-Sloan; Julian Kim; Charles L Wiggins; Phyllis A Wingo Journal: J Am Acad Dermatol Date: 2011-11 Impact factor: 11.527
Authors: Michael Coory; Peter Baade; Joanne Aitken; Mark Smithers; G Roderick C McLeod; Ian Ring Journal: Cancer Causes Control Date: 2006-02 Impact factor: 2.506
Authors: Clarisse Héry; Laufey Tryggvadóttir; Thorgeir Sigurdsson; Elínborg Olafsdóttir; Bardur Sigurgeirsson; Jon G Jonasson; Jon H Olafsson; Mathieu Boniol; Graham B Byrnes; Jean-François Doré; Philippe Autier Journal: Am J Epidemiol Date: 2010-09-02 Impact factor: 4.897
Authors: Jason E Frangos; Lyn M Duncan; Adriano Piris; Rosalynn M Nazarian; Martin C Mihm; Mai P Hoang; Briana Gleason; Thomas J Flotte; Hugh R Byers; Raymond L Barnhill; Alexa B Kimball Journal: J Am Acad Dermatol Date: 2011-12-09 Impact factor: 11.527
Authors: Alexander Katalinic; Annika Waldmann; Martin A Weinstock; Alan C Geller; Nora Eisemann; Ruediger Greinert; Beate Volkmer; Eckhard Breitbart Journal: Cancer Date: 2012-04-19 Impact factor: 6.860
Authors: Anne E Cust; Bruce K Armstrong; Chris Goumas; Mark A Jenkins; Helen Schmid; John L Hopper; Richard F Kefford; Graham G Giles; Joanne F Aitken; Graham J Mann Journal: Int J Cancer Date: 2011-05-15 Impact factor: 7.396
Authors: Mousumi Banerjee; Christopher D Lao; Lauren M Wancata; Daniel G Muenz; Megan R Haymart; Sandra L Wong Journal: Melanoma Res Date: 2016-02 Impact factor: 3.599
Authors: Caroline Chang; Era Caterina Murzaku; Lauren Penn; Naheed R Abbasi; Paula D Davis; Marianne Berwick; David Polsky Journal: Am J Public Health Date: 2014-09-11 Impact factor: 9.308
Authors: Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava Journal: Lancet Oncol Date: 2014-05 Impact factor: 41.316